Navigation Links
Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207,for BPH

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Apr 18, 2007 - Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today completion of a new 42 month follow-up study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company's two Phase 1-2 studies initiated in 2003. Individuals in the study were assessed for symptomatic improvement, treatment outcomes, and durability of efficacy. Patients in the study were assessed 3 1/2 years after NX-1207 treatment. The Company expects to conclude analysis of the data in the next 1-2 weeks and will be reporting the results once they are completed.

NX-1207 has successfully completed three U.S. trials to date. The company's most recently reported trial, a Phase 2 double-blind, placebo controlled, randomized study, showed positive efficacy and safety results for NX-1207 after 3 months in patients with BPH. Overall, patients treated with NX-1207 showed after 3 months a mean improvement of 9.35 points in AUA Symptom Score values, the standard scale used to evaluate BPH drugs and treatments. This improvement compares favorably to the 3.5 to 5 points reported in published studies of currently approved drugs for BPH and reached statistical significance when compared to placebo. Subjects treated with NX-1207 also showed an overall significant reduction in mean prostate volume. The results of the trial demonstrated the excellent safety and side effect profile of NX-1207. Subjects treated with NX-1207 had no serious side effects. In particular, patients given NX-1207 had no (0%) significant sexual side effects.

BPH afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.

More information about Nymox is availab
'"/>




Page: 1 2

Related medicine technology :

1. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
2. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
3. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
4. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
5. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
6. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
7. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
8. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
9. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Nymox Reports Completion New Month Follow Study for BPH
(Date:4/1/2015)... GLEN BURNIE, Md. , April 1, 2015 ... in patient recruitment solutions for the clinical research ... to help with a dermatology study that was ... its expert recruitment strategies and customized site support ... was screening and enrolling, and also increased the ...
(Date:4/1/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kz78wm/medical_device ) ... Device Studies: Clinical Evidence" conference to their ... specifically for those who are involved in gathering ... diagnostic products. Clinical data is required for all ... appropriate clinical evidence has grown substantially in the ...
(Date:4/1/2015)... Md. , April 1, 2015  RegeneRx ... today announced that a new medical paper has ... beta 4 (TB4) in patients with severe dry ... the study and the physicians stated that statistically ... severe dry eye were seen at various time ...
Breaking Medicine Technology:CSSi Quadruples Screening Activity and Speeds Enrollment for Pediatric Dermatology Study 2Medical Device Studies: Clinical Evidence Seminar - London, UK, 13th, 14th of May 2015 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 3
... May 27 The Department of Veterans Affairs (VA) ... arm that easily allows those with severe limb loss ... arm is a high-tech example of how VA researchers ... of artificial limbs to meet Veterans, lifestyle and medical ...
... data with PROSTVAC(TM) - a promising, late-stage vaccine,candidate for the ... Q&A session at the ASCO Annual Meeting. , ... EDT to 10 AM EDT. , ... At the Q&A session, Bavarian Nordic,s ...
Cached Medicine Technology:VA Studies Advanced Prosthetic Arm 2
(Date:4/1/2015)... 2015 When annoying or concerning skin ... or weeks for an appointment with a dermatologist is ... day appointments haven’t been possible within dermatology. However, in ... have noticed demand for this level of service and ... important relief or answers to dermatological issues are to ...
(Date:4/1/2015)... 2015 SkillSurvey, the leading provider of ... lifecycle, and the premiere provider of on-line automated reference ... a webinar on “Using Big Data to Recruit Millennials.” ... resources officer of MorseLife, a nationally recognized provider of ... their families in Palm Beach County. , “As the ...
(Date:4/1/2015)... 2015 Franklin University, one of the ... the establishment of the Greta J. Russell Medical Mutual ... through the generous gift of $100,000 from Medical Mutual ... of Medical Mutual to University representatives, Dr. David ... Advancement & Strategic Relations. , “We are grateful ...
(Date:4/1/2015)... NC (PRWEB) April 01, 2015 Doctors ... immunotherapy drug tremelimumab is more effective against mesothelioma at ... the research on its website. Click here to ... 29 patients at the University Hospital of Siena with ... grow after standard chemotherapy. When these patients received monthly ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Eighty seven ... athletics grants from California Casualty . Many of ... reduced-cost lunches and subsequently have fewer and fewer dollars ... after California Casualty Chairman Emeritus Thomas R. Brown, who ... to the classroom. Since its inception in 2011, ...
Breaking Medicine News(10 mins):Health News:Dermatology Associates of Wisconsin and Forefront Dermatology Answers Patients' Needs With Unmatched Availability In Sheboygan and Sheboygan Falls 2Health News:SkillSurvey Hiring Expert Series Continues with Webinar Featuring MorseLife 2Health News:SkillSurvey Hiring Expert Series Continues with Webinar Featuring MorseLife 3Health News:Franklin University Receives Gift to Create the Greta J. Russell Medical Mutual of Ohio Scholarship 2Health News:Franklin University Receives Gift to Create the Greta J. Russell Medical Mutual of Ohio Scholarship 3Health News:New Research Finds Immunotherapy Drug May Fight Mesothelioma Better at Higher Doses, According to Surviving Mesothelioma 2Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 2Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 3Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 4Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 5
... increasing number of countries can now take advantage of ... of osteoporosis. , FRAX, which is freely available ... was developed by Professor John A. Kanis and colleagues ... at the University of Sheffield Medical School in the ...
... Calif., Jan. 30 Diagnosoft, Inc., an innovator ... assists in diagnosis, staging and therapeutic monitoring of ... Diagnosoft(R) SENC. Strain-encoding, or SENC, is a ... measure regional contraction, or relaxation, of the heart,s ...
... LAKES, N.J., Jan. 30 Medco Health Solutions, Inc. (NYSE: ... full-year 2008 financial results in a press release before the ... release, management will hold a conference call to review the ... To access the live conference call via telephone: ...
... -- Tianyin,Pharmaceutical, Co., Inc. (NYSE Alternext: TPI), a ... based in Chengdu, China,today announced that the Company ... previously announced stock repurchase program. These shares will ... of outstanding shares of its,common stock. , ...
... of Trimlife ( www.trimlife.com ), a nutritional supplement company ... Company, LLC of Fort Lee, NJ, commonly known as ... product Lipitone ( www.lipitone.com ) and other supplements.TNC plans ... additional wellness products and services on an aggressive timetable, ...
... CEO of America,s Health Insurance Plans (AHIP), today issued ... to reauthorize and expand the State Children,s Health Insurance ... is an essential component of comprehensive health care reform. ... by voting to help ensure that no child falls ...
Cached Medicine News:Health News:FRAX tool now available for use in 12 countries 2Health News:Diagnosoft(R) Introduces Its Third MRI Analysis Innovation 2Health News:Medco Announces Date for Fourth-Quarter and Full-Year 2008 Financial Results 2Health News:Tianyin Pharmaceutical Co., Inc. Begins Initial Share Buyback under its Repurchase Program 2Health News:Tianyin Pharmaceutical Co., Inc. Begins Initial Share Buyback under its Repurchase Program 3Health News:The Neutraceutical Company, LLC Grows Wellness Enhancement Business with Acquisition of North Dakota Based Trimlife.com 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: